Faraday Pharmaceuticals is a biopharmaceutical company focused on the research and development of elemental reducing agents. These therapeutic agents have potential applications for treatment of critical care illnesses.
September 23, 2016, SEATTLE – Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of elemental reducing agents for critical care medicine, today announced the start of a Phase 1 clinical trial evaluating its lead compound FDY-5301.
September 3, 2015, SEATTLE – Faraday Pharmaceuticals today announced the appointment of Stephen A. Hill, M.D., as Chief Executive Officer.
July 8, 2014, Seattle – Faraday Pharmaceuticals today announced it has been funded by a Series A purchase of preferred shares.